Specifically, mutations in the MTHFR gene can increase the incidence of hyperhomocysteinemia, which could be ameliorated by the addition of COMT inhibitors to therapy, presenting a possibility for clinical interventions based on pharmacogenomic testing. The gene discussed is MTHFR; the disease is hyperhomocysteinemia.